Patent Assignment
Reel/Frame 057544/0803
Security Interest
Recorded: 2021-09-20
Pages: 14
Assignor
ARBOR PHARMACEUTICALS, LLC
Executed: 2021-09-20
Assignee
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
IL1-1145/54/63, P.O. BOX 6026, CHICAGO, ILLINOIS, 60680-6026
Covered Properties
(75)
Methods for Synthesis of Prodrugs from 1-Acyl-Alkyl Derivatives and Compositions Thereof
Orally Administered Dosage Forms of Gaba Analog Prodrugs Having Reduced Toxicity
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
A Transdermal Patch Composition for Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency
Composition For Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Crystalline Form of Y-Aminobutyric Acid Analog
Treating or Preventing Restless Legs Syndrome Using Prodrugs of Gaba Analogs
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Methods for Synthesis of Prodrugs from 1-Acyl-Alkyl Derivatives and Compositions Thereof
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment-Resistant Strains of Head Lice
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Crystalline Form of a (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrug and Methods of Use
Enantiomerically Resolving Acyloxyalkyl Thiocarbonates Used in Synthesizing Acyloxyalkyl Carbamate Prodrugs
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Methods of Synthesizing N-Hydroxysuccinimidyl Carbonates
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Sustained Release Oral Dosage Forms of an R-Baclofen Prodrug
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Crystalline Form of a (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrug and Methods of Use
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Methods of Using Prodrugs of Pregabalin
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
Application:
13/973,542 →
Publication:
US 2014/0056973
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application:
13/973,622 →
Publication:
US 2014/0056978
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Pharmaceutical Compositions of Dimethyl Fumarate
Sotalol Compositions and Uses of the Same
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Method of Making Monomethyl Fumarate
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Application:
14/449,513 →
Publication:
US 2015/0038499
Crystalline Forms of (N,N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Pharmaceutical Compositions of Fumaric Acid Esters
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Crystalline Forms of (N,N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Crystalline Forms of (N, N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Sotalol Compositions and Uses of the Same
Crystalline Forms of (N, N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Non-Aqueous Liquid Nimodipine Compositions
Topical Avermectin Formulations and Methods For Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
Application:
15/968,364 →
Publication:
US 2018/0242584
Pharmaceutical Compositions of Fumaric Acid Esters
Pharmaceutical Compositions of Dimethyl Fumarate
Sotalol Compositions and Uses of the Same
Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
Application:
16/403,288 →
Publication:
US 2019/0256480
Non-Aqueous Liquid Nimodipine Compositions
Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs Thereof
Application:
16/566,696 →
Publication:
US 2020/0000758
Non-Aqueous Liquid Nimodipine Compositions
Crystalline Form of y-Aminobutyric Acid Analog
Application:
16/741,113 →
Publication:
US 2020/0283376
Pharmaceutical Compositions of Dimethyl Fumarate
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Application:
16/912,123 →
Publication:
US 2020/0323804
Sotalol Compositions and Uses of the Same
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application:
17/159,576 →
Publication:
US 2021/0145755
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Application:
17/166,672 →
Publication:
US 2021/0228525
Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
Application:
17/188,422 →
Publication:
US 2021/0179573
Related Assignments
(15)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name
Aug 16, 2013
From: TOPAZ PHARMACEUTICALS LLC
To: TOPAZ PHARMACEUTICALS INC.
Reel/Frame 031031/0051 →
Merger
Aug 16, 2013
From: TOPAZ PHARMACEUTICALS INC.
To: SANOFI - TOPAZ, INC.
Reel/Frame 031024/0502 →
Corrective Assignment to Correct the Execution Date of Inventor Garry T. Gwozdz Previously Recorded on Reel 020836 Frame 0391. Assignor(S) Hereby Confirms the Execution Date of Inventor Garry T. Gwozdz Is 03/26/2008.
Aug 23, 2013
From: GWOZDZ, GARRY T.; SPRING, NICHOLAS
To: TOPAZ PHARMACEUTICALS LLC
Reel/Frame 031076/0144 →
Assignment of Assignor's Interest
Jun 4, 2015
From: GALLOP, MARK A.; CUNDY, KENNETH C.; ZHOU, CINDY X.; YAO, FENMEI
To: XENOPORT, INC.
Reel/Frame 035788/0560 →
Security Interest
Nov 11, 2015
From: ARBOR PHARMACEUTICALS, LLC
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS AGENT
Reel/Frame 037013/0177 →
Assignment of Intellectual Property Security Agreement
Nov 15, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037112/0069 →
Assignment of Assignor's Interest
Dec 2, 2015
From: SANOFI-TOPAZ INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 037190/0575 →
Security Interest
Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
Assignment of Assignor's Interest
Apr 20, 2018
From: ARBOR PHARMACEUTICALS, LLC
To: XENOPORT, INC.
Reel/Frame 046449/0306 →
Assignment of Assignor's Interest
Jul 25, 2018
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 046633/0753 →
Release of Security Interest
Aug 11, 2021
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 057142/0980 →
Release of Security Interest
Aug 31, 2021
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 057346/0837 →
Release of Security Interest
Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
Release of Security Interest
Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
Confirmatory Grant of Security Interest in United States Patents
Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →